Antioxidative effects of fluvastatin, and its major metabolites

被引:14
作者
Nakashima, A
Ohtawa, M
Masuda, N
Morikawa, H
Bando, T
机构
[1] Novartis Pharma KK, Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan
[2] Novartis Pharma KK, Takarazuka Res Inst, Takarazuka, Hyogo 6650042, Japan
来源
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN | 1999年 / 119卷 / 01期
关键词
antioxidant effect; HMG-CoA reductase inhibitor; fluvastatin; pravastatin; probucol;
D O I
10.1248/yakushi1947.119.1_93
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fluvastatin (FV) is a highly potent inhibitor of 3-hydroxy-3-methylgrutaryl-CoA (HMG-CoA) reductase. Recently, its antioxidant effect caused by inhibiting the formation of low density lipoproteins (LDL) in vitro has been reported. In this study, we reported the antioxidant effects of FV and its major metabolites in human (M-2, M-3, M-4, M-5, and M-7) on lipid peroxidation using rat liver microsomes. The extent of NADPH- induced microsomal (Ms) lipid peroxidation was determined by the thiobarbituric acid (TBA) assay. The antioxidant effect of each compound was shown as the percentage of inhibition on the formation of TEA reactive substances (TBARS) against the vehicle control. Probucol (PR), a potent antioxidant drug, was used as a reference control. The concentration of each compound in this experiment was set at 0.1 mM (final cone.). FV inhibited the formation of TEARS by 30 to 60% without depending on the used Ms concentrations (0.025-0.2 mg protein/ml). The antioxidant effects of M-2, M-3, and M-5 were comparable to that of FV at low Ms concentarations. At the highest Ms concentration, however, the antioxidant effects of these metabolites were considerably higher than that of FV. Inhibition of the formation of TEARS by M-4 or M-7 was approximately 30% of the control and independent of the used Ms concentrations. The antioxidant effect of PR was comparable to those of M-2, M-3, and M-5 in this study. Pravastatin (PV), a potent inhibitor of HMG-CoA reductase, reduced the formation of TEARS around 20% at 0.25 or 0.5 mg protein/ml of Ms concentrations. But the value of percentage of inhibition was around 5% at 0.1 or 0.2 mg protein/ml of Ms concentrations. In conclusion, the antioxidant effects of FV, M-2, M-3, and M-5 were found to be comparable to that of PR.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 8 条
[1]  
DAIN JG, 1993, DRUG METAB DISPOS, V21, P567
[2]   OXIDATION OF ESTERIFIED ARACHIDONATE BY RAT-LIVER MICROSOMES [J].
DAVIS, HW ;
SUZUKI, T ;
SCHENKMAN, JB .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1987, 252 (01) :218-228
[3]   Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL [J].
Hussein, O ;
Schlezinger, S ;
Rosenblat, M ;
Keidar, S ;
Aviram, M .
ATHEROSCLEROSIS, 1997, 128 (01) :11-18
[4]   RELATIONSHIP BETWEEN MALONDIALDEHYDE PRODUCTION AND ARACHIDONATE CONSUMPTION DURING NADPH-SUPPORTED MICROSOMAL LIPID-PEROXIDATION [J].
JORDAN, RA ;
SCHENKMAN, JB .
BIOCHEMICAL PHARMACOLOGY, 1982, 31 (07) :1393-1400
[5]  
KATHAWALA FG, 1991, MED RES REV, V11, P121
[6]   Novel indole-2-carboxamide and cycloalkeno[1,2-b]indole derivatives, structure-activity relationships for high inhibition of human LDL peroxidation [J].
KuehmCaubere, C ;
Caubere, P ;
JamartGregoire, B ;
NegreSalvayre, A ;
BonnefontRousselot, D ;
BizotEspiard, JG ;
Pfeiffer, B ;
Caignard, DH ;
GuardiolaLemaitre, B ;
Renard, P .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (08) :1201-1210
[7]   PHARMACOKINETICS OF FLUVASTATIN AFTER SINGLE AND MULTIPLE DOSES IN NORMAL VOLUNTEERS [J].
TSE, FLS ;
JAFFE, JM ;
TROENDLE, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (07) :630-638
[8]  
YUAN J, 1991, ATHEROSCLEROSIS, V87, P145